Thus, BCMA—CD19 dual-target CAR-NK cells were developed to simultaneously eradicate plasma cells and precursor populations, potentially preventing relapse arising from residual CD19+ myeloma progenitors. Here, CD19 is linked to plasma cell myeloma.